{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:56:43Z","timestamp":1792432603018,"version":"4.5.0"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Clinical trials frequently reported anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) associated with cardiac adverse drug events (AEs) but minimal postmarketing data. We aimed to research real-world cardiac disorders associated with ALK-TKIs based on the Food and Drug Administration Adverse Event Reporting System (FAERS).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    Extract reports from the FAERS from the first quarter of 2016 to the second quarter of 2021 were obtained. Data mining of cardiac disorders associated with ALK-TKIs was carried out using disproportionality analysis to determine the clinical characteristics of AEs.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    In total, 605 cases were screened out. These events were found to be more prevalent in patients \u226545\u00a0years (50.74%) and women (50.74%). The onset time of cardiac disorders was variable and concentrated within 2\u00a0months, with a median time of 33\u00a0days. The outcomes tended to be poor, with 20.93% fatality proportion. Cardiac arrhythmia was a common adverse event of ALK-TKIs, especially bradycardia. Crizotinib and lorlatinib showed positive signals in cardiac disorders, especially in heart failure, and brigatinib presented no signals. The study also found that myocarditis caused by ceritinib and cardiomyopathy caused by lorlatinib may be potential new adverse drug reactions.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    ALK-TKIs were reported more frequently in cardiotoxicity than other drugs and could often manifest earlier. We also found potential new AE signals in specific drugs and need more clinical studies to confirm. Our study helps fill the safety information of ALK-TKIs in the heart and provides directions for further research.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2022.858279","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T06:41:48Z","timestamp":1647499308000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":33,"title":["Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Associated Cardiotoxicity: A Recent Five-Year Pharmacovigilance Study"],"prefix":"10.3389","volume":"13","author":[{"given":"Yihan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chencheng","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xucheng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1378\/chest.116.6.1564","article-title":"Bloody Pericardial Effusion in Patients with Cardiac Tamponade: Is the Cause Cancerous, Tuberculous, or Iatrogenic in the 1990s?","volume":"116","author":"Atar","year":"1999","journal-title":"CHEST"},{"key":"B2","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.lungcan.2014.09.011","article-title":"Concomitant EGFR Mutation and ALK Rearrangement in Lung Adenocarcinoma Is More Frequent Than Expected: Report of a Case and Review of the Literature with Demonstration of Genes Alteration into the Same Tumor Cells","volume":"86","author":"Baldi","year":"2014","journal-title":"Lung Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative Signal Detection Using Spontaneous ADR Reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1634\/theoncologist.2018-0380","article-title":"Clinical Management of Adverse Events Associated with Lorlatinib","volume":"24","author":"Bauer","year":"2019","journal-title":"Oncologist"},{"key":"B5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.lungcan.2020.04.011","article-title":"Efficacy and Safety of ALK Inhibitors in ALK-Rearranged Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis","volume":"144","author":"Breadner","year":"2020","journal-title":"Lung Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1056\/NEJMoa1007056","article-title":"Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor","volume":"363","author":"Butrynski","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus Crizotinib in ALK-Positive Non-small-cell Lung Cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"107498","DOI":"10.1016\/j.intimp.2021.107498","article-title":"Immune-related Adverse Events Associated with Immune Checkpoint Inhibitors: An Updated Comprehensive Disproportionality Analysis of the FDA Adverse Event Reporting System","volume":"95","author":"Chen","year":"2021","journal-title":"Int. Immunopharmacol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.jtho.2019.03.002","article-title":"Efficacy and Safety of Ceritinib (450 Mg\/d or 600 Mg\/d) with Food versus 750-mg\/d Fasted in Patients with ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results from the ASCEND-8 Study","volume":"14","author":"Cho","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"22137","DOI":"10.18632\/oncotarget.25154","article-title":"Systematic Review and Meta-Analysis of Selected Toxicities of Approved ALK Inhibitors in Metastatic Non-small Cell Lung Cancer","volume":"9","author":"Costa","year":"2018","journal-title":"Oncotarget"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1158\/1078-0432.Ccr-11-2906","article-title":"Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-small Cell Lung Cancer","volume":"18","author":"Doebele","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"B12","unstructured":"Drugs@FDA: FDA-Approved Drugs"},{"key":"B13","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/1759-7714.12613","article-title":"ALK-rearrangement in Non-small-cell Lung Cancer (NSCLC)","volume":"9","author":"Du","year":"2018","journal-title":"Thorac. Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1177\/0092861512453041","article-title":"Adverse Reaction Signaling and Disproportionality Analysis: An Update","volume":"46","author":"Faich","year":"2012","journal-title":"Drug Inf. J"},{"key":"B15","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13104-015-1126-8","article-title":"Effective Crizotinib Schedule for an Elderly Patient with ALK Rearranged Non-small-cell Lung Cancer: a Case Report","volume":"8","author":"Fukuizumi","year":"2015","journal-title":"BMC Res. Notes"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/s1470-2045(14)70362-6","article-title":"Safety and Activity of Alectinib against Systemic Disease and Brain Metastases in Patients with Crizotinib-Resistant ALK-Rearranged Non-small-cell Lung Cancer (AF-002JG): Results from the Dose-Finding Portion of a Phase 1\/2 Study","volume":"15","author":"Gadgeel","year":"2014","journal-title":"Lancet Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.rmr.2019.05.040","article-title":"Diffuse Infiltrative Lung Disease, Pericarditis, Pleural Effusion and Ceritinib Hypersensitivity","volume":"36","author":"Gaillard","year":"2019","journal-title":"Rev. Mal Respir."},{"key":"B18","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/nrc3580","article-title":"Mechanistic Insight into ALK Receptor Tyrosine Kinase in Human Cancer Biology","volume":"13","author":"Hallberg","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.3892\/ol.2015.3003","article-title":"Primary Signet-Ring Cell Carcinoma of the Lung Treated with Crizotinib: A Case Report","volume":"9","author":"Hao","year":"2015","journal-title":"Oncol. Lett."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e0787","DOI":"10.1097\/cad.0000000000000787","article-title":"Treatment of ALK-Rearranged Non-small-cell Lung Cancer with Brigatinib as Second or Later Lines: Real-World Observations from a Single Institution","volume":"30","author":"Hochmair","year":"2019","journal-title":"Anticancer Drugs"},{"key":"B21","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.2147\/cmar.S190098","article-title":"The Safety and Serious Adverse Events of Approved ALK Inhibitors in Malignancies: a Meta-Analysis","volume":"11","author":"Hou","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13045-015-0122-8","article-title":"Novel ALK Inhibitors in Clinical Use and Development","volume":"8","author":"Iragavarapu","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ajco.12754","article-title":"Treatment of ALK-Rearranged Non-small Cell Lung Cancer: A Review of the Landscape and Approach to Emerging Patterns of Treatment Resistance in the Australian Context","author":"Itchins","year":"2017","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"107832","DOI":"10.1016\/j.yebeh.2021.107832","article-title":"Drug-induced Liver Injury Associated with Antiseizure Medications from the FDA Adverse Event Reporting System (FAERS)","volume":"117","author":"Kamitaki","year":"2021","journal-title":"Epilepsy Behav."},{"key":"B25","first-page":"1637","article-title":"A Super-aged Patient with Advanced ALK-Positive NSCLC and Malignant Pericardial Effusion Causing Cardiac Tamponade","volume":"45","author":"Kasai","year":"2018","journal-title":"Gan To Kagaku Ryoho"},{"key":"B26","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.critrevonc.2018.11.004","article-title":"Safety Issues with the ALK Inhibitors in the Treatment of NSCLC: A Systematic Review","volume":"134","author":"Kassem","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic Lymphoma Kinase Inhibition in Non-small-cell Lung Cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1158\/2159-8290.Cd-16-1123","article-title":"Targeting ALK: Precision Medicine Takes on Drug Resistance","volume":"7","author":"Lin","year":"2017","journal-title":"Cancer Discov."},{"key":"B29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2165\/00002018-200932010-00002","article-title":"Determinants of Under-reporting of Adverse Drug Reactions: a Systematic Review","volume":"32","author":"Lopez-Gonzalez","year":"2009","journal-title":"Drug Saf."},{"key":"B30","unstructured":"Medical Dictionary for Regulatory Activities"},{"key":"B31","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2169\/internalmedicine.55.5076","article-title":"Promising Effect of Crizotinib on Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer in an Elderly Patient with a Poor Performance Status: A Case Report and Literature Review","volume":"55","author":"Matsuo","year":"2016","journal-title":"Intern. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s00280-017-3253-5","article-title":"Effect of Alectinib on Cardiac Electrophysiology: Results from Intensive Electrocardiogram Monitoring from the Pivotal Phase II NP28761 and NP28673 Studies","volume":"79","author":"Morcos","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/s1470-2045(13)70095-0","article-title":"Safety and Activity of Crizotinib for Paediatric Patients with Refractory Solid Tumours or Anaplastic Large-Cell Lymphoma: a Children's Oncology Group Phase 1 Consortium Study","volume":"14","author":"Moss\u00e9","year":"2013","journal-title":"Lancet Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"56","DOI":"10.14740\/wjon1092w","article-title":"A Case Series of Two Patients Presenting with Pericardial Effusion as First Manifestation of Non-small Cell Lung Cancer with BRAF Mutation and Expression of PD-L1","volume":"9","author":"Mufti","year":"2018","journal-title":"World J. Oncol."},{"key":"B35","unstructured":"NCCN Guidelines Non-small Cell Lung Cancer2022"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1158\/1538-7445.AM10-1673","article-title":"Abstract 1673: A Pharmacokinetics\/pharmacodynamics Evaluation of the Concentration-QTc Relationship of PF-02341066 (PF-1066), an ALK and C-MET\/HGFR Dual Inhibitor Administered Orally to Patients with Advanced Cancer","volume":"70","author":"Nickens","year":"2010","journal-title":"Cancer Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"100315","DOI":"10.1016\/j.esmoop.2021.100315","article-title":"Postmarketing Safety of Anaplastic Lymphoma Kinase (ALK) Inhibitors: an Analysis of the FDA Adverse Event Reporting System (FAERS)","volume":"6","author":"Omar","year":"2021","journal-title":"ESMO Open"},{"key":"B38","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/cam4.622","article-title":"Factors Associated with Sinus Bradycardia during Crizotinib Treatment: a Retrospective Analysis of Two Large-Scale Multinational Trials (PROFILE 1005 and 1007)","volume":"5","author":"Ou","year":"2016","journal-title":"Cancer Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1002\/cncr.28040","article-title":"Heart Rate Decrease during Crizotinib Treatment and Potential Correlation to Clinical Response","volume":"119","author":"Ou","year":"2013","journal-title":"Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/s1470-2045(11)70232-7","article-title":"Effect of Crizotinib on Overall Survival in Patients with Advanced Non-small-cell Lung Cancer Harbouring ALK Gene Rearrangement: a Retrospective Analysis","volume":"12","author":"Shaw","year":"2011","journal-title":"Lancet Oncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the Transforming EML4-ALK Fusion Gene in Non-small-cell Lung Cancer","volume":"448","author":"Soda","year":"2007","journal-title":"NATURE"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","article-title":"Lorlatinib in Patients with ALK-Positive Non-small-cell Lung Cancer: Results from a Global Phase 2 Study","volume":"19","author":"Solomon","year":"2018","journal-title":"Lancet Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"B46","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.resinv.2014.06.005","article-title":"Anaplastic Lymphoma Kinase Rearrangement in Lung Cancer: its Biological and Clinical Significance","volume":"52","author":"Toyokawa","year":"2014","journal-title":"Respir. Investig."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1159\/000518081","article-title":"Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC","volume":"14","author":"Ulhoi","year":"2021","journal-title":"Case Rep. Oncol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A Comparison of Measures of Disproportionality for Signal Detection in Spontaneous Reporting Systems for Adverse Drug Reactions","volume":"11","author":"Van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B49","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3892\/or.2020.7851","article-title":"Safety and Efficacy of Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors in Non-small C-ell L-ung C-ancer (Review)","volume":"45","author":"Wang","year":"2021","journal-title":"Oncol. Rep."},{"key":"B50","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1378\/chest.118.3.744","article-title":"Prognostic Role of Pericardial Fluid Cytology in Cardiac Tamponade Associated with Non-small Cell Lung Cancer","volume":"118","author":"Wang","year":"2000","journal-title":"CHEST"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.jtho.2018.06.012","article-title":"Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer","volume":"13","author":"Wu","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/s2213-2600(19)30053-0","article-title":"Alectinib versus Crizotinib in Untreated Asian Patients with Anaplastic Lymphoma Kinase-Positive Non-small-cell Lung Cancer (ALESIA): a Randomised Phase 3 Study","volume":"7","author":"Zhou","year":"2019","journal-title":"Lancet Respir. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.858279\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T06:41:52Z","timestamp":1647499312000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.858279\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,17]]},"references-count":52,"alternative-id":["10.3389\/fphar.2022.858279"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.858279","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.741818429.793592114","asserted-by":"object"}]},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,17]]},"article-number":"858279"}}